Table 1.
Summary of studies investigated the effect of targetable genomic alterations on survival in metastatic CRC.
| Alteration | Therapy | Number of Patients | ORR (%) | Median DFS (Months) | Author/Reference | Year of Publication |
|---|---|---|---|---|---|---|
| BRAF V600E | D + T + P | 83 | 18 | NR | Corcoran et al./[34] | 2018 |
| V + I + C | 19 | 35 | 7.7 | Hong et al./[35] | 2016 | |
| V | 21 | 5 | 2.1 | Kopetz et al./[36] | 2015 | |
| V + P | 15 | 13 | 3.2 | Yaeger et al./[37] | 2015 | |
| D + T | 43 | 12 | 3.5 | Corcoran et al./[38] | 2015 | |
| V | 10 | 0 | 4.5 | Hyman et al./[39] | 2015 | |
| V + C | 27 | 23 | 3.7 | |||
| HER2 amplification | Tras + Pert | 34 | 38 | NR | Hainsworth et al./[40] | 2018 |
| Tras + Lap | 27 | 30 | 5 | Sartore-Bianchi et al./[41] | 2016 | |
| NTRK fusion | Laro | 4 | 50 | NA | Drilon et al. [42] | 2018 |
| ALK fusion | Ceritinib | 1 | NA | NA | Yakirevich et al./[43] | 2016 |
CRC, colorectal cancer; ORR, objective response rate; DFS, disease-free survival; D, dabrafenib; T, trametinib; P, panitumumab; NR, not reached; V, vemurafenib; I, irinotecan; C, cetuximab; Tras, trastuzumab; Pert, pertuzumab; Lap, lapatinib; Laro, larotrectinib; NA, not applicable.